Table 2.
Adjusted risk for secondary outcomes for subjects treated with 4 g/acetaminiophen/day
| |
Extended dosing |
ALT increase > 10 IU/L |
ALT increase >50% above baseline |
||||
|---|---|---|---|---|---|---|---|
| Variable | Odds ratio | 95% Confidence interval | Odds ratio | 95% Confidence interval | Odds ratio | 95% Confidence interval | |
|
Female (vs Male) |
1.47 |
0.64 to 3.73 |
1.03 |
0.53 to 2.03 |
1.21 |
0.61 to 2.39 |
|
|
Race |
|
|
|
|
|
|
|
|
Caucasian |
1.0 |
Ref |
1.0 |
Ref |
1.0 |
Ref |
|
|
Black |
1.71 |
0.47 to 6.26 |
3.56 |
1.02 to 12.45 |
1.80 |
0.54 to 5.99 |
|
|
Hispanic |
1.86 |
0.79 to 4.40 |
1.45 |
0.66 to 3.2 |
1.67 |
0.75 to 3.69 |
|
|
Other |
1.85 |
0.58 to 5.91 |
1.40 |
0.50 to 3.96 |
1.81 |
0.63 to 5.24 |
|
|
Age (per yr) |
1.01 |
0.98 to 1.04 |
1.02 |
0.99 to 1.04 |
1.02 |
1.00 to 1.05 |
|
|
Baseline ALT (Per IU/L) |
1.03 |
0.98 to 1.08 |
1.01 |
0.97 to 1.05 |
0.96 |
0.92 to1.00 |
|
|
BMI |
0.98 |
0.93 to 1.04 |
0.98 |
0.93 to 1.03 |
0.99 |
0.94 to 1.04 |
|
| No ethanol use | 1.81 | 0.81 to 4.1 | 0.90 | 0.42 to 1.92 | 0.89 | 0.42 to 1.88 | |